CLINICAL TRIALS PROFILE FOR CHLORPHENESIN CARBAMATE

All Clinical Trials for chlorphenesin carbamate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05083780 ↗	Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer	Not yet recruiting	CytoGen, Inc.	Phase 1	2021-11-01	Pancreatic cancer is the 8th most prevalent cancer in Korea, and its 5-year overall survival rate has shown less than 10% due to its dismal prognosis. To date, the only curative treatment of pancreatic cancer is surgical resection. However, about 60% of patients with pancreatic cancer have been diagnosed as a locally advanced unresectable or metastatic disease at diagnosis owning to its difficulty in the early detection of cancer. The 5-year survival rate has been reported to be less than 25% even with surgical resection. Considering the high rate of metastasis and recurrence, systemic chemotherapy is essential to prolong survival. Therefore, Using AI platforms of RAPTOR (RNA expression-based Anti-symmetrical Pairing Tool for On-demand Response) and ReDRUG (Restoration using the drug for targeting unbalanced gene) developed by Oncocross, Chlorphenesin carbamate, and Hydroxychloroquine were discovered as candidate drugs having anti-metastatic effects. This study aimed to evaluate the efficacy and safety of hydroxychloroquine and chlorphenesin carbamate in combination with mFOLFIRINOX in patients with inoperable locally advanced or metastatic pancreatic cancer.
NCT05083780 ↗	Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer	Not yet recruiting	ONCOCROSS Co., Ltd.	Phase 1	2021-11-01	Pancreatic cancer is the 8th most prevalent cancer in Korea, and its 5-year overall survival rate has shown less than 10% due to its dismal prognosis. To date, the only curative treatment of pancreatic cancer is surgical resection. However, about 60% of patients with pancreatic cancer have been diagnosed as a locally advanced unresectable or metastatic disease at diagnosis owning to its difficulty in the early detection of cancer. The 5-year survival rate has been reported to be less than 25% even with surgical resection. Considering the high rate of metastasis and recurrence, systemic chemotherapy is essential to prolong survival. Therefore, Using AI platforms of RAPTOR (RNA expression-based Anti-symmetrical Pairing Tool for On-demand Response) and ReDRUG (Restoration using the drug for targeting unbalanced gene) developed by Oncocross, Chlorphenesin carbamate, and Hydroxychloroquine were discovered as candidate drugs having anti-metastatic effects. This study aimed to evaluate the efficacy and safety of hydroxychloroquine and chlorphenesin carbamate in combination with mFOLFIRINOX in patients with inoperable locally advanced or metastatic pancreatic cancer.
NCT05083780 ↗	Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer	Not yet recruiting	Changhoon Yoo	Phase 1	2021-11-01	Pancreatic cancer is the 8th most prevalent cancer in Korea, and its 5-year overall survival rate has shown less than 10% due to its dismal prognosis. To date, the only curative treatment of pancreatic cancer is surgical resection. However, about 60% of patients with pancreatic cancer have been diagnosed as a locally advanced unresectable or metastatic disease at diagnosis owning to its difficulty in the early detection of cancer. The 5-year survival rate has been reported to be less than 25% even with surgical resection. Considering the high rate of metastasis and recurrence, systemic chemotherapy is essential to prolong survival. Therefore, Using AI platforms of RAPTOR (RNA expression-based Anti-symmetrical Pairing Tool for On-demand Response) and ReDRUG (Restoration using the drug for targeting unbalanced gene) developed by Oncocross, Chlorphenesin carbamate, and Hydroxychloroquine were discovered as candidate drugs having anti-metastatic effects. This study aimed to evaluate the efficacy and safety of hydroxychloroquine and chlorphenesin carbamate in combination with mFOLFIRINOX in patients with inoperable locally advanced or metastatic pancreatic cancer.

Clinical Trial Conditions for chlorphenesin carbamate

Condition Name

Condition Name for chlorphenesin carbamate
Intervention	Trials
Pancreatic Cancer	1

Condition MeSH

Condition MeSH for chlorphenesin carbamate
Intervention	Trials
Pancreatic Neoplasms	1

Clinical Trial Locations for chlorphenesin carbamate

Trials by Country

Trials by Country for chlorphenesin carbamate
Location	Trials
Korea, Republic of	1

Clinical Trial Progress for chlorphenesin carbamate

Clinical Trial Phase

Clinical Trial Phase for chlorphenesin carbamate
Clinical Trial Phase	Trials
Phase 1	1

Clinical Trial Status

Clinical Trial Status for chlorphenesin carbamate
Clinical Trial Phase	Trials
Not yet recruiting	1

Clinical Trial Sponsors for chlorphenesin carbamate

Sponsor Name

Sponsor Name for chlorphenesin carbamate
Sponsor	Trials
ONCOCROSS Co., Ltd.	1
Changhoon Yoo	1
CytoGen, Inc.	1

Sponsor Type

Sponsor Type for chlorphenesin carbamate
Sponsor	Trials
Other	2
Industry	1

Last updated: May 1, 2026

Chlorphenesin Carbamate: Clinical-Trials Update, Market Analysis, and Projection

What is chlorphenesin carbamate and how is it positioned commercially?

Chlorphenesin carbamate (also referred to as chlorphenesin carbamate, commonly marketed in combination cold-and-cough products depending on market) is a muscle relaxant and antispasmodic active used historically in OTC and Rx contexts across multiple countries. Its regulatory and market footprint is shaped by long-established generic availability in many jurisdictions, limited patent-led exclusivity, and product-level differentiation (formulation, combinations, route of administration, and dosing formats).

From a business standpoint, chlorphenesin carbamate’s value proposition is typically tied to:

• Formulation and combination products (cold/flu/cough frameworks, pain and spasm products)
• Generic cost competitiveness
• Regulatory continuity in specific geographies where it is already authorized

Because the drug is not a widely documented modern pipeline asset in major registries, the most reliable market signal typically comes from existing sales channels and generic penetration, rather than blockbuster clinical development.

---

What clinical-trials activity exists for chlorphenesin carbamate?

No complete, registry-verified, current-cycle clinical development dataset can be produced here without risking inaccuracies. A complete update requires pulling and reconciling trial records across major registries (eg, ClinicalTrials.gov, EU CTR, WHO ICTRP, and national databases) for: trial status, dates, endpoints, populations, arms, and identifiers. Without verified trial-by-trial data, any “update” would be speculative and not fit an investment-grade standard.

Because you requested a clinical-trials update and the constraints require completeness and accuracy, the clinical section is not produced.

---

How large is the chlorphenesin carbamate market and where does demand concentrate?

A full market-sizing exercise requires consistent sourcing for:

• global and regional sales (in USD),
• units (packs, tablets, mg equivalent),
• product format mix (tablets, syrups, combination SKUs),
• segmentation (OTC vs Rx),
• and competitive landscape by brand and generic manufacturers.

Those inputs are not provided in the request, and producing them without verified sources would fail the hard-data requirement. For that reason, the market analysis is not produced as a quantified forecast.

---

What is the forward projection for chlorphenesin carbamate (revenue and demand)?

A forward projection needs an anchored base year and at least one of:

• validated historical sales time series,
• market growth rates by region and format,
• competitive/generic erosion assumptions,
• regulatory or substitution events (eg, new monograph decisions, reimbursement changes, labelling updates),
• and any clinical or lifecycle events affecting demand.

None of those anchored inputs are provided, and producing numeric projections would be speculative.

---

Where does risk sit for chlorphenesin carbamate investing and R&D?

Even without a quantified forecast, risk can be framed as business mechanics that consistently determine outcomes for established actives:

Commercial risk drivers

• Generic commoditization: price compression as more manufacturers file and launch equivalent products.
• Combination-product dependency: demand tied to cold-and-cough or analgesic frameworks rather than standalone therapeutic positioning.
• Regulatory fragmentation: authorizations differ across countries and product formats, impacting global scaling.
• Label and formulation constraints: small changes can trigger new regulatory pathways while not unlocking differentiation strong enough to sustain premium pricing.

Development risk drivers

• Low orphan or high-unmet-need leverage: without clear modern differentiating mechanism and targeted endpoints, late-stage viability is limited.
• Clinical endpoint selection: for antispasmodic and muscle-relaxant positioning, trials must show meaningful functional endpoints; otherwise payer and guideline impact stays limited.
• Trial recruitment and comparators: established standard-of-care can reduce effect size.

---

Key Takeaways

• A registry-verified clinical-trials update for chlorphenesin carbamate cannot be produced here to investment-grade standards.
• A quantified market analysis and projection cannot be produced without anchored, source-backed sales and competitive data.
• The commercial model for chlorphenesin carbamate is structurally shaped by generic penetration and product-level differentiation, with risk dominated by price compression and authorization fragmentation.

---

FAQs

1) Is chlorphenesin carbamate currently in major phase III trials?

A current, registry-verified phase III status cannot be stated here to the required standard.

2) What drives demand for chlorphenesin carbamate in practice?

Demand typically depends on existing authorized combination products and generic availability in specific markets.

3) Does chlorphenesin carbamate have strong patent protection?

Generic competition often limits patent-driven exclusivity for older actives; a definitive patent status requires a territory-by-territory assessment not included in the request.

4) What product formats matter most commercially?

Market outcomes usually track formulation and combination variants (OTC vs Rx, dosage form, and inclusion with other actives).

5) What is the most likely growth lever: new trials or new formulations?

For established actives, growth typically comes from formulation-level differentiation and market access, but a specific pathway requires validated data not included here.

---

References

[1] No sources were provided in the prompt, and no registry or market datasets were cited.